Overview
- 5 inspections across 5 sites are on record.
- 1 Form 483 observation is attributed to this investigator.
- Most recent recorded activity is 2019-11-18.
At a glance
Inspections
5
Sites
5
Observations
1
Career since
Nov 2012
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| PPD Development, L.P. | 18 Nov 2019 | Human Drugs | |
| Sun Pharmaceutical Industries (prev. Ranbaxy) | 12 Jan 2018 | Human Drugs | |
| Celerion Switzerland AG | 11 Apr 2014 | Human Drugs | |
| International Pharmaceutical Research Center (IPRC) | 21 Nov 2012 | ||
| Padagis Israel Pharmaceuticals Ltd | 13 Nov 2012 |
Sites inspected
PPD Development, L.P.Richmond, United States1 insp.
Sun Pharmaceutical Industries (prev. Ranbaxy)Gurugram, India1 insp.
Celerion Switzerland AGFehraltorf, Switzerland1 insp.
International Pharmaceutical Research Center (IPRC)Amman, Jordan1 insp.
Padagis Israel Pharmaceuticals LtdYerucham, Israel1 insp.
Co-investigators
Investigators who share inspections with this person.
Peter R Lenahan2 shared
Huixia Zhang1 shared
Stephanie C Mangigian1 shared
Seongeun Cho1 shared
Barbara T Carmichael1 shared
Full investigator report
Get the verbatim findings behind Sam H Haidar's 1 observation
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site